The FDA has approved Praluent, a new cholesterol-lowering medicine for people with established heart disease whose risk is not adequately controlled by existing statin drugs. It is administered through an injection and its long-term effects are unknown. The approval of this drug marks a significant advancement in the battle against heart disease, particularly for patients who have been difficult to treat due to high levels of LDL cholesterol. However, the new drug's cost may pose financial challenges down the line.